ORIX saw no growth in patent filings in April and highest growth of 1.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of ORIX‘s patent filings and grants. Buy the databook here.
ORIX has been focused on protecting inventions in United States(US) with three publications in Q2 2024
The United States(US) Patent Office dominates the patent grants with nearly 75% of grants. The United States(US), and European Patent Office(EPO) patent Office are among the top ten patent offices where ORIX is filings its patents. Among the top granted patent authorities, ORIX has 75% of its grants in United States(US) and 25% in European Patent Office(EPO).
Becton Dickinson and Co and Johnson & Johnson could be the strongest competitors for ORIX
Patents related to autonomous vehicles and electronic medical record (emr) systems lead ORIX's portfolio
ORIX has the highest number of patents in autonomous vehicles followed by, electronic medical record (emr) systems and healthtech. For autonomous vehicles no patents were filed and 10% of patents were granted in Q2 2024.
Controls and modules related patents lead ORIX portfolio followed by cockpits and instrumentation, and active and passive safety
ORIX has highest number of patents in controls and modules followed by cockpits and instrumentation, active and passive safety, petrochemicals, and healthcare it.
For comprehensive analysis of ORIX's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.